The Value of Self-Care in Public Health: Insights and Implications for Europe

By Rene Pretorius

July 2, 2025

Summary
Self-care in public health is a critical pillar of public health in Europe. It enables individuals to manage minor ailments independently while easing pressure on healthcare systems. By using non-prescription medicines, devices, and supplements, self-care cuts costs, saves time, and boosts productivity. Evidence shows that the value of self-care in public health amounts to annual savings of €36 billion and averted productivity losses of €10 billion.

Key Insights
Reported study findings highlight self-care’s economic and social value. Europe avoids €36 billion yearly by managing 1.2 billion minor health issues through self-care. This includes €26 billion in medical expenses and €10 billion in productivity losses. Self-care also reduces GP workloads. It equals needing 120,000 extra doctors or 2.4 more hours daily for current practitioners. Consumer behavior is shifting toward prevention. 84% take preventive measures, and 67% spend over €21 monthly on health aids.

Background Context
Research shows self-care’s role in tackling healthcare challenges. The AESGP notes it empowers individuals with low-cost solutions for minor ailments. EU eHealth initiatives improve access to electronic records. The eHealth score reached 83% in 2024, supporting self-care goals.

Implications
For health economics, self-care offers a scalable, cost-effective solution. It helps strained systems as populations age and chronic diseases rise. Stronger policies could optimize resources, letting providers focus on complex cases. Public health efforts can align with preventive trends, reducing reliance on costly interventions. Barriers like uneven regulations and education gaps may limit uptake. Future steps include digital health tools to enhance self-care, matching EU digital goals.

Reference url

Recent Posts

Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU

By João L. Carapinha

March 4, 2026

EMA's Push for Microbiome Medicinal Products Guidance EMA's Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection paper to guide non-clinical development of microbiome...
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance The CHMP Febru...